Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03635099 · ClinicalTrials.gov registry record · Phase 2
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT03635099 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 274 participants.
The verdict
NCT03635099, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through 24 weeks of treatment
Interventions
- DRUG Placebo (fasted)
- DRUG BI 25 mg (fasted)
- DRUG BI 50 mg (fasted)
- DRUG BI 100 mg (fasted)
- DRUG BI 200 mg (fasted)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2021-05-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03635099
The ClinicalTrials.gov registry entry for NCT03635099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo (fasted) is the first listed.
NCT03635099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03635099 about?
NCT03635099 is a clinical study titled "This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is". The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through 24 weeks of treatment
What is the current status of trial NCT03635099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2018-09-17. Estimated completion is 2021-05-26.
What interventions are being tested in trial NCT03635099?
The interventions under investigation include: Placebo (fasted) (DRUG), BI 25 mg (fasted) (DRUG), BI 50 mg (fasted) (DRUG), BI 100 mg (fasted) (DRUG), BI 200 mg (fasted) (DRUG).
Who is sponsoring clinical trial NCT03635099?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.